ERBB2 and breast cancer: Furthermore, anthracyclines are reportedly less effective against HER2-negative than HER2-positive breast cancers (Gennari et al, 2008), whereas the relapse-preventative effect of UFT is not affected by HER2 status (Toi et al, 2007).